Publication date: November 07, 2025

The Act of 21 February 2019 (Journal of Laws of 2025, item 259) established a new state institution in the medical sector – the Medical Research Agency. According to Article 1, Section 7 of this Act, the Agency’s objective is to support innovative activities in healthcare, with particular emphasis on the development of non-commercial clinical trials and research experiments. One of its tasks is to support the biomedical sector by financing scientific research and development, as well as strengthening the national capacity to conduct non-commercial clinical trials. Between 2019 and 2021, the Agency contracted research projects worth approximately PLN 1 billion – 50% of the projects concerned specialization projects in oncology and cardiology, which accounted for 67% of the research budget. More importantly, the Agency was tasked with designing the Government Biomedical Sector Development Plan for 2022–2031, for which a PLN 2 billion budget was secured, originating from two sources: the National Recovery Plan and funds from the Medical Research Agency, subsidized by the Ministry of Health. Biomedicine is a field of medicine that utilizes the achievements of biological, biochemical, biophysical, and biotechnological sciences and is widely used in the early diagnosis and treatment of diseases. It utilizes innovative technologies and research results on a large scale. The global biomedical market is experiencing steady growth. Poland aspires to become a leader in this field in Eastern Europe, a goal that cannot be achieved without a unified strategy, hence the decision to create the Plan.

More